72.19.Z - Scientific research and development activities
20 - Manufacture of chemicals and chemical products
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
32 - Other manufacturing of products
72.11.Z - Scientific research and development activities
72.20.Z - Scientific research and development in social sciences and humanities
74 - Other professional, scientific and technical activities
2021 | 2022 | 2023 | ||
---|---|---|---|---|
M PLN | M PLN | M PLN | % | |
Gross profit (loss) | -1 | -1,8 | -1,4 | 19,3 |
EBITDA | -1 | -1,7 | -1,4 | 16,9 |
Short time liabilities | 0,3 | 0,5 | 0,3 | -34 |
Equity capital | 4,8 | 3 | 1,6 | -47,4 |
Operating profit (EBIT) | -1 | -1,8 | -1,5 | 17,8 |
Assets | 12,3 | 10,8 | 11,2 | 3,5 |
Net profit (loss) | -1 | -1,8 | -1,4 | 19,3 |
Cash | 7 | 2,1 | 0,8 | -62,5 |
Net income from sale | 0 | 0 | 0 | 0 |
Liabilities and provisions for liabilities | 7,5 | 7,7 | 9,5 | 23,6 |
Working assets | 11,9 | 8,7 | 9,4 | 7,8 |
Depreciation | 0 | 0,1 | 0,1 | -35,6 |
% | % | % | p.p. | |
Profitability of capital | -20,9 | -58,7 | -90 | -31,3 |
Equity capital to total assets | 39,3 | 28,3 | 14,4 | -13,9 |
Gross profit margin | -12 641,7 | -9317,3 | -7518,1 | 1799,2 |
EBITDA Margin | -12 389,7 | -8854,4 | -7358,6 | 1495,8 |
Days | Days | Days | Days | |
Short term commitment turnover cycle | 11 758 | 9523 | 6288 | -3235 |
Current financial liquidity indicator | 46.127891540527344 | 17.28557014465332 | 28.226482391357422 | 10,9 |
Net dept to EBITDA | -0.2557789385318756 | -3.032201051712036 | -5.973504543304443 | -3 |
Opinie dotyczące usług, produktów oraz działalności firmy nie są weryfikowane